Page last updated: 2024-12-10

sq-641

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SQ-641: a MurX inhibitor with antitubercular activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3013049
CHEMBL ID96062
SCHEMBL ID13618308
MeSH IDM000607401

Synonyms (14)

Synonym
CHEMBL96062 ,
decanoic acid 5-{carbamoyl-[3,4-dihydroxy-6-(7-methyl-2-oxo-azepan-3-ylcarbamoyl)-3,4-dihydro-2h-pyran-2-yloxy]-methyl}-2-(2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl)-4-methoxy-tetrahydro-furan-3-yl ester
[(2r,3r,4r,5s)-5-[(1r)-2-amino-1-[[(2s,3s,4s)-3,4-dihydroxy-6-[[(3s,7r)-7-methyl-2-oxo-azepan-3-yl]carbamoyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-oxo-ethyl]-2-(2,4-dioxopyrimidin-1-yl)-4-methoxy-tetrahydrofuran-3-yl] decanoate
rs-118641
sq-641
[(2r,3r,4r,5s)-5-[(1r)-2-amino-1-[[(2s,3s,4s)-3,4-dihydroxy-6-[[(3s,7r)-7-methyl-2-oxoazepan-3-yl]carbamoyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-oxoethyl]-2-(2,4-dioxopyrimidin-1-yl)-4-methoxyoxolan-3-yl] decanoate
254449-23-5
.alpha.-l-talofuranuronamide, 1-deoxy-5-o-(4-deoxy-n-((3s,7r)-hexahydro-7-methyl-2-oxo-1h-azepin-3-yl)-.beta.-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-, 2-decanoate
49D8WPZ5YL ,
SCHEMBL13618308
unii-49d8wpz5yl
alpha-l-talofuranuronamide, 1-deoxy-5-o-(4-deoxy-n-((3s,7r)-hexahydro-7-methyl-2-oxo-1h-azepin-3-yl)-beta-l-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2h)-pyrimidinyl)-3-o-methyl-, 2-decanoate
bdbm50221509
Q27259275
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID210951Inhibitory concentration required against Translocase I2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID144031Antimycobacterial activity against Mycobacterium intracellular ATCC 1954 E-32003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID144442Antimycobacterial activity was determined against Mycobacterium smegmatis SANK750752003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID144144Antimycobacterial activity against Mycobacterium kansasii ATCC 124782003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
AID143696Antimycobacterial activity against Mycobacterium avium NIHJ16052003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]